ReviewCNS drugs2014
Neuropsychiatric adverse events associated with statins: epidemiology, pathophysiology, prevention and management.
Review in CNS drugs, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 57 citations in OpenAlex.
- Statins and risk of amyotrophic lateral sclerosis: a systematic review and meta-analysis.Acta neurologica Belgica · 2022Pooled it
- Trial
- Trial
- Lipid-lowering and glucose-lowering drug targets differentially modulate antipsychotic treatment efficacy in schizophrenia.Cell reports. Medicine · 2026Article
- Genetic association of lipid-lowering drug target genes with erectile dysfunction and male reproductive health.Frontiers in endocrinology · 2024Article
- Aggression in Women with Schizophrenia Is Associated with Lower HDL Cholesterol Levels.International journal of molecular sciences · 2022Article
- The Impact of Quarantine on Pain Sensation among the General Population in China during the COVID-19 Pandemic.Brain sciences · 2022Article
- PCSK9 Inhibitors and Neurocognitive Adverse Drug Reactions: Analysis of Individual Case Safety Reports from the Eudravigilance Database.Drug safety · 2021Article
- Formal comment on "Systematic review of the predictors of statin adherence for the primary prevention of cardiovascular disease".PloS one · 2019Article
- Risk of Neuropsychiatric Adverse Effects of Lipid-Lowering Drugs: A Mendelian Randomization Study.The international journal of neuropsychopharmacology · 2018Article
- Do Statins Have Antidepressant Effects?CNS drugs · 2017Review
- Mood, Personality, and Behavior Changes During Treatment with Statins: A Case Series.Drug safety - case reports · 2016Article
- Erythromycin Induced Nightmares.Journal of neurogastroenterology and motility · 2016Article
- Toward Omics-Based, Systems Biomedicine, and Path and Drug Discovery Methodologies for Depression-Inflammation Research.Molecular neurobiology · 2016Review
- Comparative evaluation between chitosan and atorvastatin on serum lipid profile changes in hyperlipidemic cats.Iranian journal of veterinary research · 2016Article
- PCSK9 inhibitors and neurocognitive adverse events: exploring the FDA directive and a proposal for N-of-1 trials.Drug safety · 2015Article
- Rosa damascena oil improves SSRI-induced sexual dysfunction in male patients suffering from major depressive disorders: results from a double-blind, randomized, and placebo-controlled clinical trial.Neuropsychiatric disease and treatment · 2015Article
- Statin use and risk of depression: a Swedish national cohort study.BMC psychiatry · 2014Observational
- Article
- Association of statin use with sleep disturbances: data mining of a spontaneous reporting database and a prescription database.Drug safety · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Statins, or 3-hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors, such as lovastatin, atorvastatin, simvastatin, pravastatin, fluvastatin, rosuvastatin and pitavastatin, are cholesterol-lowering drugs used in clinical practice to prevent coronary heart disease. These drugs are generally well tolerated and have been rarely associated with severe adverse effects (e.g. rhabdomyolysis). Over the years, case series and data from national registries of spontaneous adverse drug reaction reports have demonstrated the occurrence of neuropsychiatric reactions associated with statin treatment. They include behavioural alterations (severe irritability, homicidal impulses, threats to others, road rage, depression and violence, paranoia, alienation, antisocial behaviour); cognitive and memory impairments; sleep disturbance (frequent awakenings, shorter sleep duration, early morning awakenings, nightmares, sleepwalking, night terrors); and sexual dysfunction (impotence and decreased libido). Studies designed to investigate specific neuropsychiatric endpoints have yielded conflicting results. Several mechanisms, mainly related to inhibition of cholesterol biosynthesis, have been proposed to explain the detrimental effects of statins on the central nervous system. Approaches to prevent and manage such adverse effects may include drug discontinuation and introduction of dietary restrictions; maintenance of statin treatment for some weeks with close patient monitoring; switching to a different statin; dose reduction; use of ω-3 fatty acids or coenzyme Q10 supplements; and treatment with psychotropic drugs. The available information suggests that neuropsychiatric effects associated with statins are rare events that likely occur in sensitive patients. Additional data are required, and further clinical studies are needed.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.